News from mylan inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 22, 2014, 07:30 ET

Mylan Launches First Generic Version of Vivelle-DOT®

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day,...

Dec 17, 2014, 09:00 ET

Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference

 Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will...

Dec 11, 2014, 07:30 ET

Mylan Launches Generic Robaxin® Injection

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL...

Dec 11, 2014, 07:00 ET

Mylan Launches First Generic Version of Orapred ODT®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30...

Dec 10, 2014, 07:30 ET

Mylan Launches One of First Available Generic Versions of Celebrex® Capsules

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first...

Dec 08, 2014, 05:01 ET
Mylan and World TeamTennis executives announce the title sponsor extension of Mylan World TeamTennis and Mylan WTT Smash Hits on Sunday evening in London at the Mylan WTT Smash Hits charity event.  From left to right - Mylan WTT ownership group member Andy Roddick, Mylan WTT co-founder Billie Jean King, Mylan CEO Heather Bresch, Mylan Chairman Robert J. Coury, Sir Elton John and Mylan WTT CEO/Commissioner Ilana Kloss.  Photo: Jordan Mansfield/Getty Images

World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017

 World TeamTennis (WTT), the innovative leader in professional team tennis competition, and Mylan (Nasdaq: MYL), one of the world's leading...

Dec 04, 2014, 10:00 ET

Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and...

Dec 01, 2014, 21:00 ET

Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS

Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and...

Dec 01, 2014, 21:00 ET

Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS

OTTAWA, Dec. 1, 2014 /CNW Telbec/ - Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds...

Dec 01, 2014, 07:00 ET

Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences,...

Nov 25, 2014, 07:30 ET

Mylan Confirms First-to-File Patent Challenge Relating to BREVIBLOC®

Mylan Inc. (Nasdaq: MYL) today confirmed that it and several subsidiaries have been sued by Baxter International, Inc., Baxter Healthcare...

Nov 07, 2014, 08:00 ET
Mylan

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors

Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help...

Nov 05, 2014, 07:30 ET

Mylan Launches Generic Loestrin 24 Fe®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous...

Oct 30, 2014, 16:05 ET

Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16

 Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2014. Third Quarter...

Oct 30, 2014, 12:48 ET

Mylan Launches Generic Viramune XR®

Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of...

Oct 27, 2014, 12:34 ET
http://www.multivu.com/players/English/7160152-mylan-specialty-epipen4schools-program-anaphylaxis-preparedness/gallery/image/170fc165-1cf8-46bd-b606-c27e835d5e04.HR.jpg

EpiPen4Schools® Program Enhances Support of National Movement to Improve Anaphylaxis Preparedness and Access to Emergency Treatment in Schools

Mylan Specialty, the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced new EpiPen4Schools®...

Oct 06, 2014, 07:30 ET

Mylan Launches Generic Combivir®

 Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the...

Oct 03, 2014, 07:00 ET

Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range

 Mylan Inc. (Nasdaq: MYL) today announced that it expects third quarter adjusted diluted earnings per share to be in the range of $1.12 to...

Sep 16, 2014, 07:30 ET
Mylan (PRNewsFoto/Mylan)

Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®

 Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical...

Sep 15, 2014, 06:30 ET
Mylan (PRNewsFoto/Mylan)

Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries

 Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences,...